Toward Tailored Chemo

A group at UCSF is bringing precision medicine to chemotherapies, with a predictive model for drug responses based on single gene deletions.

Despite advances in immuno-oncology and targeted therapies, nearly 95% of cancer patients receive chemotherapy as “the backbone of their cancer care,” according to Sourav Bandyopadhyay, an assistant professor of bioengineering and therapeutic sciences at the University of California San Francisco (UCSF)...